ASXL1 and juvenile myelomonocytic leukemia: JMML outcome is associated with a dose-dependent effect for RAS pathway activation and accumulation of additional recurrent mutations in genes involved in the polycomb repressive complex 2 (PRC2-ASXL1) and gene transcription/signaling (SETBP1 and JAK3)27–29.